Saturday 17 October 2026
Export ANL’s income statement to Excel — free account
Adlai Nortye Ltd. Sponsored ADR
Adlai Nortye Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.0 million, roughly unchanged from fiscal 2023. Dividend growth for five consecutive years.
11.07
1.02
−8.44%
Follow ANL
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 7.82 | 1.85 | 0.88 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | 19.30 | 17.48 | 2.89 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 130 | 127 | 123 | 109 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.04 | 0.00 | 0.05 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 46 | — | 5 | — | 5 | ||||
| Gross margin, % | — | — | — | — | — | 100.00 | — | 100.00 | — | 100.00 | |||||
| EBT | — | — | — | — | — | (57) | (59) | (109) | (52) | (36) | |||||
| EBT margin, % | — | — | — | — | — | (123.95) | 0.00 | (2,184.56) | 0.00 | (710.56) | |||||
| Net income | — | — | — | — | — | (57) | (59) | (109) | (52) | (36) | |||||
| Depreciation | — | — | — | — | — | 1 | 1 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 5.39 | 0.00 | 0.35 | 0.00 | 0.16 | ||||
| Earnings | — | — | — | — | — | (6.68) | (6.93) | (7.26) | (1.62) | (1.11) | |||||
| Cash flow | — | — | — | — | — | (0.36) | (5.10) | (3.92) | (1.62) | (1.05) | |||||
| Capex | — | — | — | — | — | (0.13) | (0.15) | (0.01) | 0.00 | (0.01) | |||||
| Free cash flow | — | — | — | — | — | (0.49) | (5.24) | (3.94) | (1.63) | (1.05) | |||||
| Book value | — | — | — | — | — | (21.87) | (28.45) | 5.19 | 0.80 | (0.26) | |||||
| Shares, m | — | — | — | — | — | 8 | 8 | 14 | 32 | 32 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 | |||||
| EV/Sales | — | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 | |||||
| EV/FCF | — | — | — | — | — | 0.00 | — | 0.00 | — | (0.01) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (3) | (43) | (57) | (52) | (33) | ||||
| Capex | — | — | — | — | — | (1) | (1) | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | (4) | (44) | (57) | (52) | (34) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 107 | (246) | 52 | 19 | (15) | ||||
| Total debt | — | — | — | — | — | 13 | 6 | 31 | 27 | 26 | |||||
| Net debt | — | — | — | — | — | (105) | (59) | (68) | (34) | 2 | |||||
| Shareholders’ equity | — | — | — | — | — | (185) | (241) | 75 | 25 | (8) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (57.56) | (107.73) | (51.49) | (67.22) | ||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | (615.01) | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | 0.00 | 26.21 | 123.26 | (103.19) | (414.01) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025
Charts ten years each
Adlai Nortye Ltd. Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LXRX Lexicon Pharmaceuticals, Inc. | $734.2M | — (loss-making) | — (loss-making) | −97.60% (below 0%: shrinking) | n/m | −154.09% (below 0%: shrinking) | 94.36% | (3,835.26%) | Compare |
| IMMX Immix Biopharma, Inc. | $719.6M | — (loss-making) | — | — | n/m | −116.22% (below 0%: shrinking) | — | 0.00% | Compare |
| ACHV Achieve Life Sciences, Inc. | $717.2M | — (loss-making) | — | +54.44% (above 0%: growing) | n/m | −19.01% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FDMT 4D Molecular Therapeutics, Inc. | $711.0M | — (loss-making) | — (loss-making) | +25,106.67% (above 0%: growing) | n/m | −61.28% (below 0%: shrinking) | 100.00% | (2,037.16%) | Compare |
| ANL Adlai Nortye Ltd. Sponsored ADR | $710.1M | — | — | — | — | +46.03% (above 0%: growing) | — | — | |
| OABI OmniAb, Inc. | $687.7M | — (loss-making) | — (loss-making) | +244.24% (above 0%: growing) | n/m | +211.16% (above 0%: growing) | 95.45% | (49.47%) | Compare |
| ANNX Annexon, Inc. | $682.5M | — (loss-making) | — | — | n/m | −26.41% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MDXG MiMedx Group, Inc | $682.2M | 111× | — (loss-making) | −34.73% (below 0%: shrinking) | n/m | −174.83% (below 0%: shrinking) | 68.96% | (28.69%) | Compare |
| CADL Candel Therapeutics, Inc. | $681.8M | — (loss-making) | — (loss-making) | 0.00% | n/m | −93.35% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $699.3M | — | — | +27.22% | — | −77.31% | 68.96% | (14.34%) |
Adlai Nortye Ltd. Sponsored ADR (ANL) key facts
- Concern: Adlai Nortye Ltd. Sponsored ADR reported a net loss of $35.5 million, or a loss of $1.11 per share, for fiscal 2025.
- Adlai Nortye Ltd. Sponsored ADR (ANL) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
- Adlai Nortye Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.0 million, roughly unchanged from fiscal 2023.
- As of October 16, 2026, ANL traded at $11.07, a market capitalization of $710.1 million.
- Return on equity was −414.0% and debt-to-equity 0.12.
- Its Altman Z-score is −22.05 (distress zone) for fiscal 2025.